# Erica spiculifolia Extract Potentiates Cisplatin Cytotoxicity by Reactivating p53 and Caspase-3-Dependent Apoptosis in Colorectal Carcinoma

**Authors:** Rositsa Mihaylova, Nikolay Bebrivenski, Dimitrina Zheleva-Dimitrova, Rumyana Simeonova, Vesela Lozanova, Ralitza Alexova, Vanyo Mitev, Reneta Gevrenova, Georgi Momekov

PMC · DOI: 10.3390/molecules31040710 · Molecules · 2026-02-18

## TL;DR

Erica spiculifolia extract enhances cisplatin's effectiveness in colorectal cancer by reactivating p53 and promoting apoptosis.

## Contribution

The study demonstrates a synergistic effect of Erica spiculifolia extract with cisplatin through p53 reactivation and apoptosis induction in colorectal carcinoma cells.

## Key findings

- Combination of ESE and cisplatin showed strong superadditive effects with Combination Index values below 1.
- ESE treatment restored p53 and increased apoptotic cell death in HT-29 cells.
- Kaempferol 3-O-glucoside, myricitrin, and naringenin 7-O-glucoside were identified as key bioactive compounds in ESE.

## Abstract

Resistance to apoptosis represents a major limitation of platinum-based chemotherapy in colorectal carcinoma, frequently arising from impaired p53 signaling and inefficient execution of programmed cell death. In this study, we investigated the anticancer activity of Erica spiculifolia extract (ESE) and its ability to synergistically enhance cisplatin cytotoxicity in HT-29 colorectal carcinoma cells. Cell viability was assessed using the MTT assay, followed by formal combination analysis based on the Chou–Talalay methodology. Combination experiments employed a non-constant ratio regimen in which a fixed ESE concentration (45 µg/mL) was combined with serial cisplatin dilutions (45.0–2.8 µg/mL) to define interaction behavior across multiple effect levels. Quantitative analysis revealed a strong superadditive effect, with Combination Index values well below 1 and markedly elevated Dose Reduction Indices for cisplatin, indicating substantial dose-sparing across effect levels. To elucidate the molecular basis of this synergism, apoptosis-related protein expression was profiled using a membrane-based immunoassay. Combined ESE and cisplatin treatment induced full-scale p53 reactivation, including restoration of phosphorylated p53 isoforms associated with DNA damage-dependent apoptotic signaling. Acridine orange/propidium iodide staining confirmed a pronounced increase in early and late apoptotic/necrotic cells following combination treatment. UHPLC-HRMS analysis identified kaempferol 3-O-glucoside (8830.19 ± 11.01 ng/mg dw) and myricitrin (3074 ± 3.12 ng/mg) as predominant flavonols, followed by naringenin 7-O-glucoside (5958.96 ± 9.98 ng/mg), while chlorogenic, cinnamic, quinic, and gallic acids were the main phenolic acids detected. These constituents may contribute to HT-29 cell sensitization to cisplatin.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157]
- **Proteins:** Casp3 (caspase 3), TP53 (tumor protein p53)
- **Chemicals:** cisplatin (PubChem CID 5460033), kaempferol 3-O-glucoside (PubChem CID 5282102), myricitrin (PubChem CID 5281673), naringenin 7-O-glucoside (PubChem CID 9910767), chlorogenic acid (PubChem CID 1794427), cinnamic acid (PubChem CID 444539), quinic acid (PubChem CID 6508), gallic acid (PubChem CID 370)
- **Diseases:** colorectal carcinoma (MONDO:0024331)

## Full-text entities

- **Genes:** BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, DIABLO (diablo IAP-binding mitochondrial protein) [NCBI Gene 56616] {aka DFNA64, SMAC}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, ATG5 (autophagy related 5) [NCBI Gene 9474] {aka APG5, APG5-LIKE, APG5L, ASP, SCAR25, hAPG5}, CD47 (CD47 molecule) [NCBI Gene 961] {aka IAP, MER6, OA3}, HSPB1 (heat shock protein family B (small) member 1) [NCBI Gene 3315] {aka CMT2F, HEL-S-102, HMN2B, HMND3, HS.76067, HSP27}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, BIRC2 (baculoviral IAP repeat containing 2) [NCBI Gene 329] {aka API1, HIAP2, Hiap-2, IAP-2, MIHB, RNF48}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, DCTN6 (dynactin subunit 6) [NCBI Gene 10671] {aka WS-3, WS3, p27}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, HTRA2 (HtrA serine peptidase 2) [NCBI Gene 27429] {aka MGCA8, OMI, PARK13, PRSS25}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, FADD (Fas associated via death domain) [NCBI Gene 8772] {aka GIG3, IMD90, MORT1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, BIRC7 (baculoviral IAP repeat containing 7) [NCBI Gene 79444] {aka KIAP, LIVIN, ML-IAP, MLIAP, RNF50}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, PON2 (paraoxonase 2) [NCBI Gene 5445], TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}
- **Diseases:** CRC (MESH:D015179), Cytotoxicity (MESH:D064420), ovarian cancer (MESH:D010051), breast adenocarcinoma (MESH:D001943), necrotic (MESH:D009336), injury to (MESH:D014947), disease (MESH:D004194), inflammation (MESH:D007249), Cancer (MESH:D009369), oral cancer (MESH:D009062), colon tumor (MESH:D003110), squamous cell carcinoma (MESH:D002294)
- **Chemicals:** fisetin (MESH:C017875), gentisic acid (MESH:C010925), m-hydroxybenzoic acid (MESH:C032948), Cisplatin (MESH:D002945), Propidium Iodide (MESH:D011419), Erica spiculifolia Extract (-), Myricitrin (MESH:C008577), Astragalin (MESH:C001579), MTT (MESH:C070243), p-coumaric acid (MESH:C495469), o-coumaric acid (MESH:C085894), Kaempferol 3-O-glucoside (MESH:C511963), naringenin (MESH:C005273), CO2 (MESH:D002245), L-glutamine (MESH:D005973), CGA (MESH:D002726), DMSO (MESH:D004121), syringic acid (MESH:C001945), Flavonoids (MESH:D005419), caffeic acid (MESH:C040048), epigallocatechin (MESH:C057580), ellagic acid (MESH:D004610), luteolin (MESH:D047311), vanillic acid (MESH:D014641), o-hydroxybenzoic acid (MESH:D020156), formazan (MESH:D005562), GA (MESH:D005707), Formic acid (MESH:C030544), PI (MESH:D010716), methanol (MESH:D000432), BAD (MESH:C006711), platinum (MESH:D010984), AO (MESH:D000165), flavanone (MESH:C028610), epigallocatechin gallate (MESH:C045651), flavonols (MESH:D044948), rutin (MESH:D012431), acetonitrile (MESH:C032159), hesperidin (MESH:D006569), cellulose acetate (MESH:C005062), Nitrogen (MESH:D009584), quercetin (MESH:D011794), m-coumaric acid (MESH:C043332), catechin (MESH:D002392), apigenin (MESH:D047310), CA (MESH:C029010), myricetin (MESH:C040015), Phenolic acids (MESH:C017616), ferulic acid (MESH:C004999), kaempferol (MESH:C006552), naringenin 7-O-glucoside (MESH:C529068), water (MESH:D014867), oxaliplatin (MESH:D000077150), QA (MESH:D011801), flavonol (MESH:C041477), ACN (MESH:C084683), isopropanol (MESH:D019840), vinorelbine (MESH:D000077235), aglycones (MESH:C458179), hydroxybenzoic acids (MESH:D062385)
- **Species:** Homo sapiens (human, species) [taxon 9606], Bruckenthalia spiculifolia (spike heath, species) [taxon 49138], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** MOC-5 — Mus musculus (Mouse), Squamous cell carcinoma of the mouse oral cavity, Cancer cell line (CVCL_ZD32), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), HCD — Homo sapiens (Human), Transformed cell line (CVCL_WW26), ESE — Homo sapiens (Human), Transformed cell line (CVCL_F584), HL-60 leukemia — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943122/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943122/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943122/full.md

---
Source: https://tomesphere.com/paper/PMC12943122